Abstract: This invention relates to antitumoral ecteinascidin derivatives.

Abstract: This invention relates to compounds of the formula: wherein: the substituent groups defined by R1, R2 are each independently selected of H, C(?O)R?, C1–C18 alkyl, C2–C18 alkenyl, C2–C18 alkynyl, or aryl; each of the R? groups is independently selected from the group consisting of H; OH; NO2; NH2; SH; CN; halogen; ?O; C(?O)H; C(?O)CH3; CO2H; or C1–C18 alkyl, C2–C18 alkenyl, C2–C18 alkynyl, or aryl, each of which, independently, may be substituted with one or more substituents selected from the group consisting of halogen, cyano, hydroxy, nitro, azido; alkanoyl, carboxamido, alkyl, alkenyl, alkynyl, aryloxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, aminoalkyl, carbocylic aryl having 6 or more carbons, and aralkyl; X2 is OX1 or N(X1)2 wherein each X1 is independently H, C(?O)R? where R? is as defined, C1–C18 alkyl, C2–C18 alkenyl, C2–C18 alkynyl, aryl, alkoxy, heterocyclyl, or two X1 groups together form a cyclic substituent on the nitrogen atom, or X1 is SO2CH3 when X2 is OX1, or N(X1)2 is NHCOalk